Trial Profile

A 26-week, Randomized, Open-label, Parallel-group Comparison of SAR341402 Mix 70/30 to NovoMix30 in Adult Patients with Diabetes Mellitus Using Pre-mix Insulin Analogs

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 06 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Insulin aspart (Primary) ; Insulin aspart/insulin protamine aspart
Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
Focus Registrational; Therapeutic Use
Acronyms GEMELLI M
Sponsors Sanofi; Sanofi-Aventis Recherche & Developpement

Most Recent Events

01 Jun 2022 Results of a subgroup analysis compared the efficacy, safety and Immunogenicity of biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 with Originator Insulin Aspart Mix 70/30 published in the Diabetes Therapy
14 Apr 2022 Results published in the Diabetes Therapy
08 Nov 2020 This trial has been Completed in Poland, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com